secnidazole + albendazole

secnidazole + albendazole is a combination drug regimen investigated by the University of Cambridge for the treatment and prevention of giardiasis and soil-transmitted helminthiasis in pediatric populations. Secnidazole is a nitroimidazole anti-infective that works by damaging the DNA of anaerobic protozoa like *Giardia lamblia*. Albendazole is a broad-spectrum benzimidazole anthelmintic that inhibits the polymerization of tubulin, disrupting the metabolic pathways of helminths. This specific co-administration strategy was evaluated in rural Bangladesh to assess its impact on infant growth, nutritional status, and intestinal mucosal function.

Other names

Anti-Giardia and antihelmintic treatment